Menu

Mark Peterson

Reading the market’s next move: deconstructing the deals and disruptions that move the world.

MP
Editor
Mark Peterson

About This Column

Mark Peterson is an analyst of the maneuvers that redefine global industry. Formerly the voice behind Strategic Transactions & Market Disruptors, Mark has expanded his lens to investigate how high-stakes deals serve as the ultimate signals of future market dominance. He specializes in deconstructing the "why" behind corporate maneuvers - dissecting M&A activity, IPOs, and strategic realignments to uncover what they telegraph about the next decade of growth and competition. His column is a destination for those who want to understand the intersection of capital, technology, and the evolving corporate landscape.

Displaying items 881-883 of 883 in total

Mark Peterson 11 months ago

Highwoods' Charlotte Bet: Balancing Growth with Portfolio Quality

Highwoods Properties' $223M acquisition of 6Hundred at Legacy Union signals a strategic shift in Charlotte’s office market, emphasizing quality and long-term stability amid evolving work trends.

Read full article
Highwoods' Charlotte Bet: Balancing Growth with Portfolio Quality
Mark Peterson 11 months ago

Middlefield Banc Corp. Signals Stability with Consistent Dividend, Eyes Ohio Growth

Regional lender Middlefield Banc Corp. announces a steady dividend, bolstered by strong Q3 performance and strategic lending in Ohio. Analysts see continued stability amidst a changing economic landscape.

Read full article
Middlefield Banc Corp. Signals Stability with Consistent Dividend, Eyes Ohio Growth
Mark Peterson 11 months ago

Cannabinoid Therapy Shows Promise for Autoimmune Diseases, Biotech Firm Files Patent

Raphael Pharmaceutical advances a novel, THC/CBD-free cannabinoid treatment for rheumatoid arthritis, filing a provisional patent and reporting positive early clinical results. Is this a breakthrough for autoimmune therapy?

Read full article
Cannabinoid Therapy Shows Promise for Autoimmune Diseases, Biotech Firm Files Patent
UCID: 2